These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review. Noguchi K; Ikawa Y Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278 [TBL] [Abstract][Full Text] [Related]
8. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. Eyre TA; Khan D; Hall GW; Collins GP Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435 [TBL] [Abstract][Full Text] [Related]
9. Primary bone anaplastic lymphoma kinase positive anaplastic large-cell lymphoma: A case report and review of the literature. Zheng W; Yin QQ; Hui TC; Wu WH; Wu QQ; Huang HJ; Chen MJ; Yan R; Huang YC; Pan HY World J Clin Cases; 2021 May; 9(14):3403-3410. PubMed ID: 34002151 [TBL] [Abstract][Full Text] [Related]
10. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242 [TBL] [Abstract][Full Text] [Related]
11. Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile. Kwatra KS; Paul PAM; Calton N; John JM; Cotelingam JD South Asian J Cancer; 2017; 6(3):129-131. PubMed ID: 28975123 [TBL] [Abstract][Full Text] [Related]
12. CD30-Positive Anaplastic Lymphoma Kinase-Negative Systemic Anaplastic Large-Cell Lymphoma in a 9-Year-Old Boy. Kim JE; Oh EH; Ro YS; Ko JY Ann Dermatol; 2016 Jun; 28(3):371-4. PubMed ID: 27274637 [TBL] [Abstract][Full Text] [Related]
13. When Lymphoma Strikes the Pancreas: A Rare Presentation of Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in a Human Immunodeficiency Virus-Positive Patient. Huang HH; Qing X J Hematol; 2023 Oct; 12(5):236-242. PubMed ID: 37936974 [TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin in anaplastic large cell lymphoma. Skarbnik AP; Smith MR Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148 [TBL] [Abstract][Full Text] [Related]
15. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. Wellmann A; Otsuki T; Vogelbruch M; Clark HM; Jaffe ES; Raffeld M Blood; 1995 Sep; 86(6):2321-8. PubMed ID: 7662979 [TBL] [Abstract][Full Text] [Related]
16. The biology and management of systemic anaplastic large cell lymphoma. Hapgood G; Savage KJ Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285 [TBL] [Abstract][Full Text] [Related]
17. Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient! Popova TN; Radinov A; Stavrov K; Temelkova I; Terziev I; Lozev I; Lukanova D; Mangarov H; Wollina U; Tchernev G Open Access Maced J Med Sci; 2018 Jul; 6(7):1275-1277. PubMed ID: 30087736 [TBL] [Abstract][Full Text] [Related]
18. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol. Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984 [TBL] [Abstract][Full Text] [Related]